LVZ Inc. Purchases 194 Shares of Stryker Co. (NYSE:SYK)

LVZ Inc. raised its position in Stryker Co. (NYSE:SYK) by 4.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,200 shares of the medical technology company’s stock after purchasing an additional 194 shares during the quarter. LVZ Inc.’s holdings in Stryker were worth $1,512,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in SYK. Creative Financial Designs Inc. ADV raised its position in Stryker by 19.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 317 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 52 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Stryker by 0.8% in the third quarter. Janney Montgomery Scott LLC now owns 64,555 shares of the medical technology company’s stock valued at $23,321,000 after buying an additional 517 shares during the period. PDS Planning Inc increased its stake in shares of Stryker by 5.5% in the third quarter. PDS Planning Inc now owns 1,422 shares of the medical technology company’s stock valued at $514,000 after buying an additional 74 shares during the period. Moloney Securities Asset Management LLC bought a new position in shares of Stryker during the third quarter worth about $1,133,000. Finally, FSM Wealth Advisors LLC lifted its stake in shares of Stryker by 2.8% in the third quarter. FSM Wealth Advisors LLC now owns 1,888 shares of the medical technology company’s stock worth $682,000 after acquiring an additional 52 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SYK shares. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Wells Fargo & Company upped their price target on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $422.15.

Stryker Trading Down 1.2 %

NYSE:SYK opened at $390.27 on Wednesday. The firm has a market capitalization of $148.92 billion, a P/E ratio of 50.29, a PEG ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company’s 50-day simple moving average is $381.45 and its 200 day simple moving average is $372.28.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share. As a group, analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.